Additionally, AML cells with FLT3 mutations are thought to be resistant to conventional chemotherapy and are found in 75% of cases after relapse, therefore making the mutated FLT3 receptor a relevant therapeutic target to improve long-term remission in AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.